The Measurement Era Has a Blind Spot: Closing the Biological Lag

We are living in what might be called the Measurement Era of medicine—a time when clinical decisions, policy, and reimbursement are increasingly driven by what can be quantified. Blood pressure readings, cholesterol levels, A1c values, and body mass index are all reported, tracked, and benchmarked. On paper, millions of Americans appear “healthy” or “controlled.”

Yet what the system measures often tells only part of the story. Beneath the numbers, bodies absorb the real burden of life: stress, scarcity, sleep disruption, and metabolic volatility. These biologic processes—central to chronic disease—are largely invisible to current metrics.

We call this gap the Biological Lag: the difference between the surrogate markers medicine relies on and the underlying physiologic processes that actually drive disease. Patients can meet every guideline and still be biologically unstable. This mismatch is not abstract—it manifests in adults experiencing heart attacks or strokes despite “controlled” lab results, in infants born into physiologic vulnerability, and in millions whose lives look fine on paper while their biology is silently failing.

This is not just a theoretical concern. My son, Matthew, saw it firsthand as a paramedic and neonatal volunteer. Patients appeared stable on charts yet required urgent intervention. Even professionals—people living and working by the rules of society—are not immune. We know this personally: during a period of extreme instability while my son trained to become a paramedic, we lived in our car. We ate irregularly. We slept poorly. The biologic toll was real. And if it could happen to us, it can happen to anyone.

The Measurement Era has given medicine incredible tools. But unless what we measure aligns with what actually drives health and disease, the system is rewarding appearances of control rather than the presence of real biologic stability. Chronic cardiometabolic disease persists in the United States not because of lack of knowledge, but because the wrong processes are being prioritized.

Closing the Biological Lag requires both a conceptual shift and new tools. One example is FMTVDM©, a method that directly quantifies regional blood flow and metabolic activity in tissues. Rather than relying solely on indirect surrogate markers, FMTVDM© measures the processes that actually determine disease progression, from inflammation and endothelial activation to thrombotic instability. By assessing what truly matters, FMTVDM© can help clinicians, researchers, and policymakers align measurement with biology.

We are not calling for more numbers for the sake of numbers. We are calling for measurement that matters—metrics capable of identifying biologic instability before it becomes disease, tools that help prevent crises rather than react to them. Modernizing measurement in this way could transform care, improve outcomes, and finally bridge the gap that has left millions of Americans invisible to the system.

The Measurement Era is here. Its promise has been enormous. But until we close the Biological Lag, its potential will remain unfulfilled. Our bodies do not wait for policy, metrics, or oversight. Measurement must catch up—or millions will continue to pay the cost.

The Measurement Era, the Biological Lag, and the FMTVDM® Solution.   This schematic contrasts what current medical systems routinely measure—surrogate markers such as blood pressure, A1c, LDL, and BMI—with the underlying biologic processes that actually drive disease. This mismatch creates The Biological Lag, where inflammation, endothelial dysfunction, metabolic stress, and thrombotic risk progress silently despite “normal” or guideline‑concordant metrics. The lower panel illustrates how FMTVDM® directly quantifies regional blood flow and metabolic activity, enabling clinicians to measure the physiologic processes that matter most. By aligning measurement with biology, FMTVDM® provides a pathway to close the Biological Lag and modernize chronic disease detection, prevention, and treatment.